ArrowMark Colorado Holdings’s Dianthus Therapeutics DNTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.83M Hold
20,788
– – 0.09% 227
2026
Q2
$2.03M Hold
20,788
– – 0.08% 224
2026
Q1
$1.74M Hold
20,788
– – 0.05% 226
2025
Q4
$857K Hold
20,788
– – 0.02% 267
2025
Q3
$818K Hold
20,788
– – 0.02% 257
2025
Q2
$387K Hold
20,788
– – 0.01% 282
2025
Q1
$377K Hold
20,788
– – 0.01% 278
2024
Q4
$453K Hold
20,788
– – 0.01% 284
2024
Q3
$569K Hold
20,788
– – 0.01% 271
2024
Q2
$538K Hold
20,788
– – 0.01% 285
2024
Q1
$624K Hold
20,788
– – 0.01% 283
2023
Q4
$216K Hold
20,788
– – ﹤0.01% 294
2023
Q3
$284K Buy
+20,788
New +$262K ﹤0.01% 288

Other funds holding DNTH

ArrowMark Colorado Holdings's DNTH Position: Q3 2026 in Review

ArrowMark Colorado Holdings held its Dianthus Therapeutics (DNTH) position steady in Q3 2026 at 20,788 shares worth $1.83M. The position accounts for 0.09% of the portfolio, ranked #227.

ArrowMark Colorado Holdings first reported a position in DNTH in Q3 2023 and has held it in 13 quarters since. The position peaked at $2.03M in Q2 2026. 275 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

  • ArrowMark Colorado Holdings held 20,788 shares of Dianthus Therapeutics worth $1.83M as of Q3 2026.
  • ArrowMark Colorado Holdings left its Dianthus Therapeutics share count unchanged in Q3 2026.
  • Dianthus Therapeutics made up 0.09% of ArrowMark Colorado Holdings's portfolio in Q3 2026, its #227 holding.
  • ArrowMark Colorado Holdings first reported a position in Dianthus Therapeutics in Q3 2023 and has held it in 13 quarters since.
  • ArrowMark Colorado Holdings's Dianthus Therapeutics position peaked at $2.03M in Q2 2026.
  • 275 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q3 2026, filed 16 Nov 2026.